32 citations
,
September 2018 in “Clinical Obstetrics and Gynecology” This article states that hormone therapy with estrogens and antiandrogens for transgender females is within an obstetrician-gynecologist's practice scope and involves careful dosing and monitoring to manage short-term thrombotic risks.
28 citations
,
October 2018 in “Clinical Obstetrics and Gynecology” This study suggests that gender-affirming testosterone therapy in transgender men is generally safe and effective with adequate screening and monitoring, although high-quality long-term studies are lacking.
9 citations
,
July 2024 in “Internal Medicine Journal” This narrative review discusses the initiation and monitoring of gender-affirming hormone therapy in Australia, noting standard testosterone use for trans men and estradiol with anti-androgens for trans women, emphasizing the importance of monitoring cardiovascular and bone health.
9 citations
,
May 2024 in “Journal of Clinical & Translational Endocrinology” This review examines existing evidence on the efficacy and safety of gender affirming hormone therapy in relation to Gender Affirmation Surgery, but reports no new clinical results.
3 citations
,
February 2025 in “Journal of the American Academy of Dermatology” This study highlights how sex steroids affect hair growth, reporting that testosterone used in masculinizing hormone therapy can lead to androgenetic alopecia in transgender individuals, while feminizing hormone therapy with estradiol and antiandrogens can reduce hirsutism.